Should You Continue to Hold Prestige Consumer Stock in Your Portfolio?

Prestige Consumer Healthcare (PBH) is experiencing growth through e-commerce, brand-building, and strategic acquisitions like Hydralyte and TheraTears, with e-commerce sales now representing a high-teens percentage of total sales. Despite these upsides, which have contributed to a 30.9% stock rally in the past year, the company faces challenges including a $1.01 billion long-term debt and potential headwinds from fluctuating foreign exchange rates, which could impact profitability; for fiscal year 2026, PBH anticipates organic revenue growth of 1% to 2% with a one percentage point foreign exchange headwind.

Analysis

Prestige Consumer Healthcare (PBH) has delivered a notable 30.9% stock appreciation over the past year, significantly outperforming industry and market benchmarks, underpinned by an attractive earnings yield of 5.6%. The company's strategic pillars include robust brand-building for core products like Hydralyte and Dramamine, continuous product innovation such as the Monistat Maintain Kit, and accretive acquisitions like TheraTears, which contribute to a diversified portfolio. A significant growth catalyst is its e-commerce channel, which achieved double-digit growth in fiscal 2025 and now represents a high-teens percentage of total sales, an increase from approximately 15% in the preceding year. Despite these operational strengths and a history of exceeding earnings estimates with an average surprise of 2.8%, PBH faces substantial financial challenges. The company carries a considerable long-term debt of $1.01 billion against $98 million in cash, reflected in a debt-to-capital ratio of 35.6% and a times interest earned multiple of 7, signaling potential constraints on its interest payment capabilities. Moreover, its international operations, accounting for 15.6% of fiscal 2025 revenue, expose PBH to foreign exchange volatility, with an anticipated one percentage point headwind in fiscal 2026. Consequently, the company projects modest organic revenue growth of 1% to 2% for fiscal 2026, with consensus estimates pointing to a 0.9% total revenue increase to $1.15 billion and EPS of $4.77, reflecting these headwinds.

Key Decisions for Investors

• Investors should weigh PBH's strong brand portfolio, e-commerce momentum (now a high-teens percentage of sales), and consistent earnings delivery against the material risks posed by its $1.01 billion long-term debt and susceptibility to foreign exchange headwinds, which are projected to temper its modest 1-2% organic revenue growth forecast for fiscal 2026.
• Closely monitor PBH's debt servicing capacity, particularly its times interest earned ratio of 7, and the actual impact of currency fluctuations on its international revenues (15.6% of total in FY25), as these factors are critical to its profitability outlook and sustaining its 5.6% earnings yield.
• Given the Zacks Rank #3 (Hold) and mixed signals including a cautious tone, investors might assess if the current valuation, following a 30.9% stock rally, adequately reflects both the growth opportunities from its diversified consumer healthcare brands and the financial risks associated with its leverage and subdued near-term growth projections.